Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: Analysis of the food and drug administration adverse event reporting system

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 3, 2013, Pages 269-276

  Deepak, Parakkal ^a   Stobaugh, Derrick J ^b   Ehrenpreis, Eli D ^b,c  

^a MAYO CLINIC   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adverse effects; Antagonists; Antibodies; Complications; Epidemiology; Immunosuppressive agents; Inflammatory bowel diseases; Inhibitors; Monoclonal; Opportunistic infections; Tumor Necrosis Factor alpha

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFECTIVE AGENT; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; GASTROINTESTINAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MYCOBACTERIOSIS; MYCOSIS; PREDICTION; RESPIRATORY TRACT INFECTION; ULCERATIVE COLITIS; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG COMBINATION; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; MICROBIOLOGY; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PARASITOLOGY; RISK; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES; VIROLOGY; YOUNG ADULT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFECTIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; ODDS RATIO; OPPORTUNISTIC INFECTIONS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84884600672     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Silverstein MD, Loflus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57.
2. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
3. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
7. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265. e1-3.
8. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238.
9. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395.
10. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidencebased Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
11. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1051-1063.
12. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012; 10: 1002-1007.
13. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936.
14. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-center cohort study. Gut 2009; 58: 501-508.
15. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
16. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009; 104: 2524-2533.
17. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-2339.
18. Lichtenstein G, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of followup in the TREAT™ registry. Am J Gastroenterol 2012; 107: 1409-1422.
19. Food and Drug Administration Adverse Event Reporting System (FAERS) data files. http://www. fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193. htm. Accessed July 31, 2012.
20. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013; 108: 99-105.
21. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156.
22. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-1429.
23. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14: 354-377.
24. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011; 106: 1594-1602.
25. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-653.
26. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; (2): CD008794.
27. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013; 7: 107-112
28. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-264.
29. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265.
30. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309: 887-895.
31. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 677-692.
32. Shale MJ, Seow CH, Cofin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 20-34.
33. Gale EA. Collateral damage: the conundrum of drug safety. Diabetologia 2009; 52: 1975-1982.
34. Stobaugh DJ, Deepak P, Ehrenpreis ED. Alleged Isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. J Am Acad Dermatol 2013, May 14. pii: SO190-9622(13)00423-4. Epub ahead of print.
35. Wallace JL, Sharkey KA. Chapter 47. Pharmacotherapy of Inflammatory Bowel Disease. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of therapeutics. 12th ed. New York: McGraw-Hill 2011. http://www. accessmedicine. com/content. aspx?aID=16675684. Accessed July 15, 2012.
36. PDR® Electronic Library™ [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically.
37. Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 4226-4227.